BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37999215)

  • 21. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response.
    Trifan A; Stratina E; Rotaru A; Stafie R; Zenovia S; Nastasa R; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals.
    Armandi A; Rosso C; Troshina G; Pérez Diaz Del Campo N; Marinoni C; Nicolosi A; Caviglia GP; Saracco GM; Bugianesi E; Ciancio A
    Biology (Basel); 2022 Aug; 11(8):. PubMed ID: 36009789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy.
    Weigand K; Peschel G; Grimm J; Müller M; Buechler C
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):444-452. PubMed ID: 36535063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus.
    Takeda H; Takai A; Iguchi E; Mishima M; Arasawa S; Kumagai K; Eso Y; Shimizu T; Takahashi K; Ueda Y; Taura K; Hatano E; Iijima H; Aoyagi H; Aizaki H; Marusawa H; Wakita T; Seno H
    Carcinogenesis; 2021 May; 42(5):672-684. PubMed ID: 33617626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.
    Salama II; Raslan HM; Abdel-Latif GA; Salama SI; Sami SM; Shaaban FA; Abdelmohsen AM; Fouad WA
    World J Hepatol; 2022 Jun; 14(6):1053-1073. PubMed ID: 35978668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
    Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
    Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
    Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
    Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness.
    Dajti E; Marasco G; Ravaioli F; Colecchia L; Ferrarese A; Festi D; Colecchia A
    JHEP Rep; 2021 Jun; 3(3):100289. PubMed ID: 34095798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
    Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
    J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury.
    Peschel G; Grimm J; Gülow K; Müller M; Buechler C; Weigand K
    Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33228201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
    Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
    BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Role of SIRT1/ FGF-21 in Taurine Protection Against Cafeteria Diet-Induced Steatohepatitis in Rats.
    Abd Elwahab AH; Ramadan BK; Schaalan MF; Tolba AM
    Cell Physiol Biochem; 2017; 43(2):644-659. PubMed ID: 28942443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
    Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
    Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.